Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Updated daily

Drug recalls

Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.

Class IITerminatedApr 12, 2023Ropinirole 2mg tabletscGMP DeviationsRemedyRepack Inc. · D-0499-2023Class IITerminatedApr 12, 2023Atorvastatin 20 mg tabletscGMP DeviationsRemedyRepack Inc. · D-0498-2023Class IITerminatedApr 12, 2023Tadalafil 5 mg tabletscGMP DeviationsRemedyRepack Inc. · D-0497-2023Class IITerminatedApr 12, 2023Simvastatin 10 mg tabletscGMP DeviationsRemedyRepack Inc. · D-0496-2023Class IITerminatedApr 12, 2023Rosuvastatin 5mg tabletscGMP DeviationsRemedyRepack Inc. · D-0495-2023Class IITerminatedApr 12, 2023Ropinirole 0.5 mg tabletscGMP DeviationsRemedyRepack Inc. · D-0494-2023Class IITerminatedApr 12, 2023Glimepiride 2 mg tabletscGMP DeviationsRemedyRepack Inc. · D-0493-2023Class IITerminatedApr 12, 2023Doxazosin 2 mg tabletscGMP DeviationsRemedyRepack Inc. · D-0492-2023Class IITerminatedApr 12, 2023Atorvastatin 10 mg tabletscGMP DeviationsRemedyRepack Inc. · D-0491-2023Class IITerminatedApr 12, 2023Aripiprazole 5mg tabletscGMP DeviationsRemedyRepack Inc. · D-0490-2023Class IITerminatedApr 12, 2023Testosterone Cypionate InjectioncGMP: complaints of crystals not redissolving into solution after warming and shaking the vials.Azurity Pharmaceuticals, Inc. · D-0489-2023Class IIOngoingApr 5, 2023Dabigatran Etexilate 150mg CapsulesCGMP Deviations: Detection of N-nitroso-dabigatran (NDAB) impurity levels above the Acceptable Daily Intake Limit.Ascend Laboratories, LLC · D-0534-2023Class IIOngoingApr 5, 2023Dabigatran Etexilate CapsulesCGMP Deviations: Detection of N-nitroso-dabigatran (NDAB) impurity levels above the Acceptable Daily Intake Limit.Ascend Laboratories, LLC · D-0533-2023Class IIOngoingApr 5, 2023Fentanyl 500mcgLack of assurance of sterility: Suspected microbial growth present on external label packaging.Apollo Care · D-0487-2023Class IITerminatedApr 5, 2023SimvastatincGMP deviationsDirect Rx · D-0486-2023Class IITerminatedApr 5, 2023SimvastatincGMP deviationsDirect Rx · D-0485-2023Class IITerminatedApr 5, 2023SimvastatincGMP deviationsDirect Rx · D-0484-2023Class IITerminatedApr 5, 2023SimvastatincGMP deviationsDirect Rx · D-0483-2023Class IITerminatedApr 5, 2023GlimepiridecGMP deviationsDirect Rx · D-0482-2023Class IITerminatedApr 5, 2023GlimepiridecGMP deviationsDirect Rx · D-0481-2023Class IITerminatedApr 5, 2023GlimepiridecGMP deviationsDirect Rx · D-0480-2023Class IITerminatedApr 5, 2023RopinirolecGMP deviationsDirect Rx · D-0479-2023Class IITerminatedApr 5, 2023RopinirolecGMP deviationsDirect Rx · D-0478-2023Class IITerminatedApr 5, 2023FinasteridecGMP deviationsDirect Rx · D-0477-2023Class IITerminatedApr 5, 2023Montelukast Sodium TabletscGMP deviationsDirect Rx · D-0476-2023Class IITerminatedApr 5, 2023Calcitonin Salmon Nasal SprayFailed Impurities/Degradation Specifications and Subpotent Drug: High Out of Specification results for a known and unknown impurity as well as low Out of Specification...Endo Pharmaceuticals, Inc. · D-0475-2023Class IOngoingMar 29, 2023Delsam Pharma's Artificial Eye OintmentNon-Sterility: FDA analysis found unopened tubes to be contaminated with bacteria.Global Pharma Healthcare Private Limited · D-0488-2023Class IIITerminatedMar 29, 2023Dofetilide CapsulesFailed Content Uniformity SpecificationsSun Pharmaceutical Industries Inc · D-0474-2023Class IIOngoingMar 29, 2023DaytranaDefective Delivery System: Out of specification for shear.Noven Pharmaceuticals Inc · D-0473-2023Class IIOngoingMar 29, 2023DaytranaDefective Delivery System: Out of specification for shear.Noven Pharmaceuticals Inc · D-0472-2023Class IIOngoingMar 29, 2023DaytranaDefective Delivery System: Out of specification for shear.Noven Pharmaceuticals Inc · D-0471-2023Class IIOngoingMar 29, 2023DaytranaDefective Delivery System: Out of specification for shear.Noven Pharmaceuticals Inc · D-0470-2023Class IITerminatedMar 29, 2023JARDIANCELabeling: Label Mix-upBoehringer Ingelheim Pharmaceuticals, Inc. · D-0468-2023Class IITerminatedMar 22, 2023Clear EyesFailed Impurities Specification: Out-of-specification (OOS) stability test result was obtained for unspecified impurity.Teva Pharmaceuticals USA Inc · D-0469-2023Class IIITerminatedMar 22, 2023Colchicine TabletsFailed Impurities/Degradation Specifications: An out-of-specification (OOS) result was observed during release testing of one lot for a related substance, i.e...Zydus Pharmaceuticals (USA) Inc · D-0467-2023Class IIITerminatedMar 22, 2023Buprenorphine Transdermal SystemFailed Impurities/Degradation Specifications: Out of specification for related substance 10-hydroxy buprenorphine N-Oxide results generated at the 18-month stability...AVEVA Drug Delivery Systems, Inc. · D-0466-2023Class IIITerminatedMar 22, 2023Buprenorphine Transdermal SystemFailed Impurities/Degradation Specifications: Out of specification for related substance 10-hydroxy buprenorphine N-Oxide results generated at the 18-month stability...AVEVA Drug Delivery Systems, Inc. · D-0465-2023Class IIIOngoingMar 22, 2023EvamistFailed Content Uniformity Specifications: The Spray Content Uniformity (SCU) requirement for Standard Deviation did not meet the requirement at the 18-month stability...Padagis US LLC · D-0464-2023Class IITerminatedMar 22, 2023Clobazam TabletsCGMP Deviations: Potential risk of Cross ContaminationBreckenridge Pharmaceutical, Inc · D-0463-2023Class IITerminatedMar 22, 2023Clobazam TabletsCGMP Deviations: Potential risk of Cross ContaminationBreckenridge Pharmaceutical, Inc · D-0462-2023

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.